128 related articles for article (PubMed ID: 7695982)
1. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
[TBL] [Abstract][Full Text] [Related]
2. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Res; 1993 Aug; 53(16):3758-64. PubMed ID: 8339288
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Kerbusch T; vanPutten JW; Groen HJ; Huitema AD; Mathĵt RA; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jul; 48(1):53-61. PubMed ID: 11488525
[TBL] [Abstract][Full Text] [Related]
5. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Cerny T; Leyvraz S; von Briel T; Küpfer A; Schaad R; Schmitz SF; Honegger P; Sessa C; Brunner J; Boddy AV
Ann Oncol; 1999 Sep; 10(9):1087-94. PubMed ID: 10572607
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of ifosfamide during a 3 day infusion.
Hartley JM; Hansen L; Harland SJ; Nicholson PW; Pasini F; Souhami RL
Br J Cancer; 1994 May; 69(5):931-6. PubMed ID: 8180026
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Granvil CP; Ducharme J; Leyland-Jones B; Trudeau M; Wainer IW
Cancer Chemother Pharmacol; 1996; 37(5):451-6. PubMed ID: 8599868
[TBL] [Abstract][Full Text] [Related]
9. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Boddy AV; Cole M; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1995; 36(1):53-60. PubMed ID: 7720176
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
Singer JM; Hartley JM; Brennan C; Nicholson PW; Souhami RL
Br J Cancer; 1998 Mar; 77(6):978-84. PubMed ID: 9528844
[TBL] [Abstract][Full Text] [Related]
11. Comparison of continuous infusion and bolus administration of ifosfamide in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Eur J Cancer; 1995; 31A(5):785-90. PubMed ID: 7640054
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
Kerbusch T; de Kraker J; Mathĵt RA; Beijnen JH
Clin Pharmacokinet; 2001; 40(8):615-25. PubMed ID: 11523727
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
[TBL] [Abstract][Full Text] [Related]
14. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer.
Haas R; Schmid H; Hahn U; Hohaus S; Goldschmidt H; Murea S; Kaufmann M; Wannenmacher M; Wallwiener D; Bastert G; Hunstein W
Eur J Cancer; 1997 Mar; 33(3):372-8. PubMed ID: 9155519
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Hoffmann W; Weidmann B; Migeod F; Könner J; Seeber S
Cancer Chemother Pharmacol; 1990; 26 Suppl():S69-70. PubMed ID: 2347053
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients.
Johnstone EC; Lind MJ; Griffin MJ; Boddy AV
Cancer Chemother Pharmacol; 2000; 46(6):433-41. PubMed ID: 11138456
[TBL] [Abstract][Full Text] [Related]
19. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
20. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]